Zurich Cantonal Bank’s Cue Biopharma CUE Stock Holding History

Zurich Cantonal Bank’s Portfolio CUE Stock Details CUE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q2	–	Sell	-109	Closed	-$16K	–	2901
2022 Q1	$16K	Hold	109	–	–	﹤0.01%	2688
2021 Q4	$37K	Hold	109	–	–	﹤0.01%	2797
2021 Q3	$48K	Hold	109	–	–	﹤0.01%	2623
2021 Q2	$38K	Hold	109	–	–	﹤0.01%	2507
2021 Q1	$40K	Hold	109	–	–	﹤0.01%	2448
2020 Q4	$41K	Hold	109	–	–	﹤0.01%	2477
2020 Q3	$49K	Hold	109	–	–	﹤0.01%	2259
2020 Q2	$80K	Buy	+109	New	+$79K	﹤0.01%	2045

Other funds holding CUE

Prosight Management Dallas, Texas $610M AUM 40.86% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

SPC

Slate Path Capital New York $6.73B AUM 95.97% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

SMH

Sanders Morris Harris Houston, Texas $172M AUM 22.54% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Carlson Capital Dallas, Texas $318M AUM 27.64% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Bleichroeder LP New York $579M AUM 94.36% 1-Year Est. Return

Zurich Cantonal Bank's CUE Position: Q2 2022 in Review

Zurich Cantonal Bank sold out of Cue Biopharma (CUE) in Q2 2022, closing a stake of 109 shares — an estimated $16K sold.

Zurich Cantonal Bank first reported a position in CUE in Q2 2020 and held it in 8 quarters. The position peaked at $80K in Q2 2020. 75 funds tracked by Wall St. Rank hold CUE as of Q2 2022.

Zurich Cantonal Bank reported no remaining Cue Biopharma position as of Q2 2022 after selling out during the quarter.
Zurich Cantonal Bank sold 109 Cue Biopharma shares in Q2 2022, an estimated $16K.
Zurich Cantonal Bank first reported a position in Cue Biopharma in Q2 2020 and held it in 8 quarters.
Zurich Cantonal Bank's Cue Biopharma position peaked at $80K in Q2 2020.
75 funds tracked by Wall St. Rank held Cue Biopharma as of Q2 2022.

Based on Zurich Cantonal Bank's 13F filing for Q2 2022, filed 9 Aug 2022.